Affinage

TSC22D4

TSC22 domain family protein 4 · UniProt Q9Y3Q8

Length
395 aa
Mass
41.0 kDa
Annotated
2026-06-10
13 papers in source corpus 12 papers cited in narrative 14 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TSC22D4 is a leucine-zipper transcriptional regulator that acts as a hepatic metabolic sensor coordinating lipid handling, glucose homeostasis, and insulin signaling (PMID:23307490, PMID:27827363, PMID:36269831). In liver, elevated TSC22D4 suppresses VLDL secretion and lipogenic gene expression, and its loss drives hypertriglyceridemia, while hepatocyte-specific deletion derepresses mitochondrial programs (TCA cycle, triglyceride metabolism) and reduces steatosis and apoptosis (PMID:23307490, PMID:35378329). It controls systemic glucose homeostasis by directly transcribing the secretory factor LCN13, and its hepatic inhibition prevents and reverses hyperglycemia, glucose intolerance, and insulin resistance in diabetes models (PMID:27827363). Mechanistically, under energy deprivation and oxidative stress TSC22D4 engages Akt1 through its intrinsically disordered D2 domain to dampen Akt phosphorylation and downstream insulin signaling, an interaction relieved by refeeding or glucose/insulin (PMID:36269831); consistent with nutrient sensing, TSC22D4 directly binds glucose at its C-terminal leucine zipper, a contact abolished by the I322W mutation that reshapes intramolecular zipper–disordered-domain contacts and reroutes its protein associations toward fatty-acid metabolism machinery. Beyond the liver, TSC22D4 operates through a recurrent NRBP1-centered axis: by binding NRBP1 it competitively blocks NRBP1-mediated ubiquitination of SALL4 to stabilize it and induce stemness genes, and suppresses NRBP1-driven degradation of TRAF6 to stabilize TRAF6 and activate NF-κB/IL-1/TNF transcriptional outputs (PMID:31864704, PMID:39869046). It additionally stabilizes NRF2 by disrupting the KEAP1–NRF2 complex through a conserved ETGE motif, activating ARE-driven antioxidant transcription and SLC7A11 to suppress ferroptosis (PMID:42248840), and is itself activated by RTK-RAS-ERK phosphorylation in carcinoma cells where it influences JUNB-P21 senescence control and CD44 splicing (PMID:31806366, PMID:37607779). TSC22D4 exists as multiple iso-/phospho-glycoforms with distinct subcellular localizations and partners, including a chromatin-associated O-GlcNAcylated form and a mitochondrial form associating with apoptosis-inducing factor (PMID:23305244).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2012 Medium

    Established that TSC22D4 has a regulated subcellular distribution and is functionally required for a cellular differentiation program, the first evidence of an active cellular role.

    Evidence Immunofluorescence/fractionation across cerebellar granule neuron differentiation plus siRNA knockdown with morphological readouts

    PMID:20878296

    Open questions at the time
    • No molecular partners or transcriptional targets identified
    • Mechanism linking localization to differentiation unknown
  2. 2013 High

    Defined TSC22D4 as a hepatic transcription factor controlling lipid metabolism, answering what physiological process it governs.

    Evidence Liver-specific overexpression and knockout in mice with VLDL secretion and lipogenic gene-expression readouts

    PMID:23307490

    Open questions at the time
    • Direct transcriptional targets in lipid control not defined
    • Upstream regulators of hepatic TSC22D4 levels unclear
  3. 2013 Medium

    Showed that TSC22D4 function is partitioned across multiple iso-/phospho-glycoforms with distinct localizations and partners, explaining how one gene reaches nucleus, cytosol, chromatin, and mitochondria.

    Evidence Biochemical fractionation, isoform-resolved co-immunoprecipitation and western blotting during neuronal differentiation

    PMID:23305244

    Open questions at the time
    • Functional consequence of each isoform not tested
    • AIF and TSC22D1.2 interactions not validated reciprocally or functionally
  4. 2016 High

    Identified LCN13 as a direct transcriptional target linking hepatic TSC22D4 to systemic glucose homeostasis, providing the first mechanistic effector of its metabolic role.

    Evidence Liver-specific knockdown/overexpression in diabetes mouse models with transcriptional and glucose-handling readouts

    PMID:27827363

    Open questions at the time
    • DNA-binding specificity and direct promoter occupancy not structurally defined
    • Whether LCN13 fully accounts for the glucose phenotype unresolved
  5. 2019 Medium

    Placed TSC22D4 in cancer signaling, both upstream of JUNB-P21 senescence control and as an NRBP1-binding stabilizer of SALL4, revealing a non-transcriptional protein-stabilization mechanism.

    Evidence CRISPR knockout with siRNA epistasis (JUNB), Co-IP, and ubiquitination/tumorsphere assays in squamous carcinoma cells

    PMID:31806366 PMID:31864704

    Open questions at the time
    • NRBP1-binding interface on TSC22D4 not mapped
    • Connection between metabolic and oncogenic functions unclear
  6. 2022 High

    Demonstrated direct, nutrient-state-dependent TSC22D4-Akt1 binding through the D2 domain, establishing the molecular basis for its modulation of insulin signaling during starvation.

    Evidence Reciprocal Co-IP, domain mapping, and liver-specific genetic reconstitution in mice with phosphorylation readouts

    PMID:36269831

    Open questions at the time
    • Structural detail of the disordered D2–Akt1 contact not resolved
    • How the same protein switches between transcriptional and Akt-binding modes unknown
  7. 2022 Medium

    Extended TSC22D4's hepatic role to fibrosis and mitochondrial control, showing it activates HSC transcriptional programs and restrains hepatocyte mitochondrial metabolism.

    Evidence Loss-of-function in hepatic stellate cells and hepatocyte-specific knockout with RNA-seq and single-nuclei RNA-seq in NASH models

    PMID:35378329 PMID:35714570

    Open questions at the time
    • Direct transcriptional targets driving fibrosis and mitochondrial signatures not pinpointed
    • Whether effects are cell-autonomous or paracrine not fully resolved
  8. 2023 Medium

    Identified RTK-RAS-ERK phosphorylation as an upstream activating input and CD44 alternative splicing as a downstream output, integrating TSC22D4 into oncogenic kinase signaling.

    Evidence Phospho-specific antibody detection, knockdown/overexpression, and xenograft assays in SCC cells

    PMID:37607779

    Open questions at the time
    • Phosphosite identity and its effect on each TSC22D4 activity not defined
    • Mechanism of splicing regulation unknown
  9. 2025 Medium

    Generalized the NRBP1 axis by showing TSC22D4 stabilizes TRAF6 to drive NF-κB/IL-1/TNF transcription, unifying its protein-stabilization role across distinct substrates.

    Evidence Co-IP, RNA-seq, siRNA knockdown, NF-κB translocation and TRAF6 ubiquitination assays in SCC cells

    PMID:39869046

    Open questions at the time
    • Determinants of substrate selectivity (SALL4 vs TRAF6) within the NRBP1 complex unknown
    • Physiological context where this pathway dominates not defined
  10. 2026 Medium

    Revealed an ETGE-motif-dependent disruption of KEAP1-NRF2 by TSC22D4, defining a direct mechanism for antioxidant activation, ferroptosis suppression, and drug resistance.

    Evidence Co-IP, NRF2 ubiquitination/stability assays, SLC7A11 and ferroptosis/sorafenib-resistance readouts in renal carcinoma cells

    PMID:42248840

    Open questions at the time
    • Structural basis of ETGE-KEAP1 engagement not solved
    • Whether this NRF2 axis operates in liver/metabolic contexts untested
  11. 2025 Medium

    Provided direct biophysical evidence that TSC22D4 is a glucose-binding protein, mapping the binding site to the C-terminal leucine zipper and offering a molecular basis for nutrient sensing.

    Evidence Thermal proteome profiling, microscale thermophoresis, UV-crosslinking MS, and I322W mutagenesis (preprint)

    Open questions at the time
    • Preprint; not yet peer-reviewed or independently confirmed
    • Functional consequence of glucose binding for transcription/Akt/NRBP1 activities not established in vivo
  12. 2024 Low

    Positioned TSC22D4 within an osmotic-stress WNK1-SPAK-NRBP1 complex via RΦ motifs, extending its scaffolding role to ion-stress signaling.

    Evidence Proximity ligation, IP-MS, and AlphaFold-3 modelling (preprint)

    Open questions at the time
    • Preprint; complex architecture is partly computational and TSC22D4-specific functional tests are limited
    • Direct binding contributions not separated from co-complex membership

Open questions

Synthesis pass · forward-looking unresolved questions
  • How TSC22D4 switches among its transcriptional, kinase-binding, scaffold, and glucose-sensing modes, and how isoform identity and post-translational modification select among them, remains unresolved.
  • No structure of full-length TSC22D4 or its functional complexes
  • Mechanism coupling glucose binding to a specific downstream activity unknown
  • Whether the NRBP1, KEAP1, and metabolic functions co-occur in the same cell type untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0140110 transcription regulator activity 2 GO:0060089 molecular transducer activity 1
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0000228 nuclear chromosome 1 GO:0005739 mitochondrion 1
Pathway
R-HSA-1430728 Metabolism 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-162582 Signal Transduction 2 R-HSA-8953897 Cellular responses to stimuli 2
Partners
AIFM1AKT1KEAP1NRBP1TSC22D1WNK1
Complex memberships
WNK1-SPAK-NRBP1 complex

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 TSC22D4 acts as a transcription factor in liver whose elevated levels inhibit hepatic VLDL secretion and lipogenic gene expression; liver-specific ablation triggers hypertriglyceridemia through induction of hepatic VLDL secretion, establishing TSC22D4 as a regulator of hepatic lipid metabolism and VLDL release. Liver-specific overexpression and ablation (knockout) in mice with metabolic phenotyping (VLDL secretion assays, gene expression analysis) EMBO molecular medicine High 23307490
2016 Hepatic TSC22D4 directly transcriptionally regulates the secretory protein lipocalin 13 (LCN13) to control systemic glucose homeostasis; hepatic TSC22D4 inhibition prevents and reverses hyperglycaemia, glucose intolerance and insulin resistance in diabetes mouse models. Liver-specific knockdown/overexpression in diabetes mouse models, transcriptional regulation assays, correlation with LCN13 levels Nature communications High 27827363
2012 TSC22D4 subcellular localization is developmentally regulated in cerebellar granule neurons (CGNs): it occupies both nuclear and cytoplasmic compartments in undifferentiated CGNs but specifically accumulates in somatodendritic and synaptic compartments upon maturation; siRNA-mediated silencing of TSC22D4 blocked CGN differentiation and inhibited neurite elongation in N1E-115 neuroblastoma cells. Immunofluorescence/fractionation in vivo and in vitro during CGN differentiation, siRNA knockdown with morphological readouts Cerebellum (London, England) Medium 20878296
2013 TSC22D4 exists in multiple iso-/phospho-glycoforms with distinct subcellular localizations and interacting partners: the 42 kDa form is cytosolic and associates with TSC22D1.2 only in undifferentiated CGNs; the 55 kDa form associates with the nuclear matrix in differentiated CGNs; the 67 kDa form enters mitochondria of differentiated CGNs and associates with apoptosis-inducing factor (AIF); the 72 kDa form is O-GlcNAcylated and phosphorylated and is chromatin-associated regardless of differentiation state. Biochemical fractionation, co-immunoprecipitation, western blotting with isoform-specific analysis during CGN differentiation The FEBS journal Medium 23305244
2019 TSC22D4 (THG-1) knockout in esophageal tumor cells induces cellular senescence through activation of the JUNB pathway, which drives transcription of the CDK inhibitor P21 (CDKN1A); siRNA-mediated knockdown of JUNB reduced P21 mRNA and reversed senescence in THG-1 KO cells, placing TSC22D4 upstream of JUNB-P21 in the senescence pathway. CRISPR/Cas9 knockout, siRNA knockdown of JUNB, RT-PCR, senescence assays Biochemical and biophysical research communications Medium 31806366
2019 TSC22D4 (THG-1) binds to NRBP1 and competitively prevents NRBP1 from binding and ubiquitinating SALL4, thereby stabilizing SALL4 protein and inducing stemness genes (NANOG, OCT4) to promote tumorsphere formation in esophageal squamous cell carcinoma cells. Co-immunoprecipitation (THG-1/NRBP1 interaction), ubiquitination assays, knockdown/overexpression with tumorsphere formation and gene expression readouts Biochemical and biophysical research communications Medium 31864704
2022 TSC22D4 directly interacts with Akt1 via its intrinsically disordered D2 domain; energy deprivation and oxidative stress promote this interaction while refeeding or glucose/insulin exposure impairs it. The TSC22D4-Akt1 interaction reduces basal Akt phosphorylation and downstream signaling during starvation, and liver-specific reconstitution experiments confirmed this interaction improves glucose handling and insulin sensitivity. Co-immunoprecipitation, domain mapping (D2 domain), liver-specific genetic reconstitution in mice, phosphorylation assays Science advances High 36269831
2022 TSC22D4 promotes TGFβ1-mediated activation of hepatic stellate cells (HSCs) and their proliferation and migration; RNA-seq revealed TSC22D4 initiates transcriptional programs associated with HSC activation, establishing a role for TSC22D4 in liver fibrosis across hepatocytes and HSCs. TSC22D4 loss-of-function in HSCs, proliferation/migration assays, RNA-sequencing Biochemical and biophysical research communications Medium 35714570
2022 Hepatocyte-specific deletion of TSC22D4 upregulates mitochondrial-related processes including the TCA cycle, mitochondrial organization, and triglyceride metabolism, reducing liver lipid accumulation, steatosis, and apoptosis; single-nuclei RNA sequencing identified a distinct TSC22D4-dependent mitochondrial gene signature in hepatocytes. Hepatocyte-specific knockout (TSC22D4-HepaKO), NASH diet models, single-nuclei RNA sequencing, metabolic phenotyping Molecular metabolism Medium 35378329
2023 TSC22D4 (THG-1) is phosphorylated by the RTK-RAS-ERK pathway in squamous cell carcinoma cells, promoting oncogene-mediated tumorigenesis; TSC22D4 also regulates alternative splicing of CD44 variants (a regulator of invasiveness, stemness, and oxidative stress resistance) downstream of RTK signaling. Phosphorylation assays, specific phospho-antibody, knockdown/overexpression in SCC cells with proliferation, invasion, and xenograft assays Cancer science Medium 37607779
2025 TSC22D4 (THG-1) binds to NRBP1, suppressing NRBP1's E3 ubiquitin ligase-mediated degradation of TRAF6, thereby stabilizing TRAF6 and promoting NF-κB nuclear translocation and activation of IL-1 and TNF pathway transcriptional targets (IL1A, IL1B, TNFA, IL8) in squamous cell carcinoma cells. Co-immunoprecipitation (THG-1/NRBP1 interaction), RNA sequencing, siRNA knockdown, NF-κB nuclear translocation assays, TRAF6 ubiquitination/degradation assays Molecular cancer research : MCR Medium 39869046
2026 TSC22D4 directly binds KEAP1 via a conserved ETGE motif, disrupting the KEAP1-NRF2 complex and preventing NRF2 ubiquitination and degradation, thereby stabilizing NRF2, activating ARE-driven transcription, and upregulating SLC7A11 to suppress ferroptosis and confer sorafenib resistance in clear cell renal cell carcinoma. Co-immunoprecipitation (TSC22D4/KEAP1 interaction), NRF2 ubiquitination assays, NRF2 stability assays, SLC7A11 expression and ferroptosis/drug resistance assays Cell death & disease Medium 42248840
2024 TSC22D4 contains two RΦ-motifs that interact with the CCTL1 domain of WNK1 and the CCT domain of NRBP1, forming a multi-subunit complex with WNK1, SPAK, and NRBP1 in response to osmotic stress; this complex is required for WNK1 pathway activation. Proximity ligation, immunoprecipitation, mass spectrometry, AlphaFold-3 structural modelling, immunoblotting bioRxivpreprint Low
2025 TSC22D4 directly binds glucose at its C-terminal leucine zipper region; mutation of isoleucine 322 to tryptophan (I322W) abolishes glucose binding. Glucose binding increases accessibility of the leucine zipper region and promotes intra-protein contacts between the C-terminal zipper and N-terminal intrinsically disordered domain; high glucose conditions promote TSC22D4 association with fatty acid metabolism machinery proteins. Thermal proteome profiling (PISA), microscale thermophoresis (MST) confirming direct glucose-protein interaction, UV-crosslinking mass spectrometry identifying binding site, site-directed mutagenesis (I322W), chemo-proteomics bioRxivpreprint Medium

Source papers

Stage 0 corpus · 13 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO molecular medicine 53 23307490
2016 Control of diabetic hyperglycaemia and insulin resistance through TSC22D4. Nature communications 30 27827363
2012 Subcellular TSC22D4 localization in cerebellum granule neurons of the mouse depends on development and differentiation. Cerebellum (London, England) 23 20878296
2022 TSC22D4 interacts with Akt1 to regulate glucose metabolism. Science advances 18 36269831
2019 Promotion of cellular senescence by THG-1/TSC22D4 knockout through activation of JUNB. Biochemical and biophysical research communications 13 31806366
2019 THG-1 suppresses SALL4 degradation to induce stemness genes and tumorsphere formation through antagonizing NRBP1 in squamous cell carcinoma cells. Biochemical and biophysical research communications 11 31864704
2013 Multiple TSC22D4 iso-/phospho-glycoforms display idiosyncratic subcellular localizations and interacting protein partners. The FEBS journal 10 23305244
2022 Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function. Molecular metabolism 7 35378329
2022 TSC22D4 promotes TGFβ1-induced activation of hepatic stellate cells. Biochemical and biophysical research communications 7 35714570
2023 Promotion of squamous cell carcinoma tumorigenesis by oncogene-mediated THG-1/TSC22D4 phosphorylation. Cancer science 5 37607779
2025 THG-1/TSC22D4 Promotes IL-1 Signaling through Stabilization of TRAF6 in Squamous Cell Carcinoma. Molecular cancer research : MCR 2 39869046
2026 TSC22D4 drives clear cell renal cell carcinoma progression and therapy resistance by stabilizing NRF2 through KEAP1 disruption. Cell death & disease 0 42248840
2025 Nanomolecular silencing of TSC22D4 mRNA via a DNAsome-siRNA for enhancing insulin sensitization in hepatocytes. Iranian journal of basic medical sciences 0 39906612

Missed literature

Know a paper Affinage missed for TSC22D4? Flag it for the maintainers and the community.

No submissions yet.